Cargando…
Beta-adrenergic receptor blockade in angiosarcoma: Which beta-blocker to choose?
Beta-blockers are currently studied to improve therapeutic options for patients with angiosarcoma. However, most of these patients have no cardiovascular co-morbidity and it is therefore crucial to discuss the most optimal pharmacological properties of beta-blockers for this population. To maximize...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520289/ https://www.ncbi.nlm.nih.gov/pubmed/36185303 http://dx.doi.org/10.3389/fonc.2022.940582 |